里昂发表报告指，石药集团与生物制药公司Madrigal完成另一项交易，涉及GLP-1小分子药物SYH2086，预付金额为1.2亿美元，里程碑金额高达19.55亿美元，另加按百分比计算的销售权利金。报告指，由于石药有10个已上市的创新品牌及30多个将于2028年前推出的创新产品，预期其核心盈利增长将于2026年起重新加速。 该行上调石药2025至27年收入预测分别1.6%、14.3%及3%，纯利预测分别上调11.8%、73.3%及11.6%，以反映对已完成及潜在授权项目的假设；目标价由13.8港元上调至17.4港元，重申“高度确信跑赢大市”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.